Healthcare Stocks

MEDIA-Blood clot drug Apixaban totally ineffective as post-Covid treatment, UK research finds - FT

  • November 28, 2022 12:09 AM GMT | Reuters
 MEDIA-Blood clot drug Apixaban totally ineffective as post-Covid treatment, UK research finds - FT

-- Source link: https://on.ft.com/3U5tlbm -- Note: Reuters has not verified this story and does not vouch for its accuracy

Read More...

MEDIA-Bristol Myers Squibb warns UK medicines levy threatens investment - FT

MEDIA-Bristol Myers Squibb warns UK medicines levy threatens investment - FT

  • November 14, 2022 05:15 AM GMT | Reuters

-- Source link: https://on.ft.com/3TwyzwE -- Note: Reuters has not verified this story and does not vouch for its accuracy

Read More...
UPDATE 2-GSK's oncology business suffers fresh blow with Zejula setback

UPDATE 2-GSK's oncology business suffers fresh blow with Zejula setback

  • November 12, 2022 12:41 AM PST | Reuters

* News follows setback to GSK's blood cancer drug Blenrep * Shares fall nearly 5% in afternoon trading (Adds detail, company response, analyst comment, shares) By Natalie Grover and Pushkala Aripaka

Read More...
UK Stocks-Factors to watch on Nov 11

UK Stocks-Factors to watch on Nov 11

  • November 11, 2022 08:16 PM PST | Reuters

Nov 11 (Reuters) - Britain's FTSE 100 index ticked higher on Friday and was up 0.03% as of 0909 GMT. * ECONOMY: Britain's economy shrank in the three months to September at the start of what is likely

Read More...
GSK to limit U.S. use of ovarian cancer drug to some populations

GSK to limit U.S. use of ovarian cancer drug to some populations

  • November 11, 2022 07:12 PM PST | Reuters

(Reuters) -Britain's GSK said on Friday it will limit the use of its ovarian cancer treatment Zejula in the United States, to patients with some genetic anomalies when given as a second option to keep

Read More...
UPDATE 1-GSK to limit U.S. use of ovarian cancer drug to some populations

UPDATE 1-GSK to limit U.S. use of ovarian cancer drug to some populations

  • November 11, 2022 07:12 PM PST | Reuters

(Adds details, background on drug) Nov 11 (Reuters) - Britain's GSK said on Friday it will limit the use of its ovarian cancer treatment Zejula in the United States, to patients with some genetic

Read More...
BRIEF-GSK Says FDA To Restrict Second-Line Maintenance Indication For Zejula

BRIEF-GSK Says FDA To Restrict Second-Line Maintenance Indication For Zejula

  • November 11, 2022 06:19 PM PST | Reuters

Nov 11 (Reuters) - GSK plc: * GSK PLC - GSK UPDATE: ZEJULA 2L IN US * GSK PLC - GSK UPDATE: ZEJULA 2L IN US * GSK: AT REQUEST OF FDA WILL RESTRICT SECOND-LINE MAINTENANCE INDICATION FOR ZEJULA TO ONLY

Read More...
UPDATE 2-GSK's oncology business suffers fresh blow with Zejula setback

UPDATE 2-GSK's oncology business suffers fresh blow with Zejula setback

  • November 12, 2022 12:41 AM GMT | Reuters

* News follows setback to GSK's blood cancer drug Blenrep * Shares fall nearly 5% in afternoon trading (Adds detail, company response, analyst comment, shares) By Natalie Grover and Pushkala Aripaka

Read More...
UPDATE 2-GSK's oncology business suffers fresh blow with Zejula setback

UPDATE 2-GSK's oncology business suffers fresh blow with Zejula setback

  • November 12, 2022 12:41 AM CET | Reuters

* News follows setback to GSK's blood cancer drug Blenrep * Shares fall nearly 5% in afternoon trading (Adds detail, company response, analyst comment, shares) By Natalie Grover and Pushkala Aripaka

Read More...
EUROPE RESEARCH ROUNDUP- Allianz, Lundin Mining, SLM Solutions

EUROPE RESEARCH ROUNDUP- Allianz, Lundin Mining, SLM Solutions

  • November 11, 2022 11:12 PM GMT | Reuters

Nov 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Allianz, Lundin Mining, and SLM Solutions, on Friday. HIGHLIGHTS * Allianz SE :

Read More...
EUROPE RESEARCH ROUNDUP- Allianz, Lundin Mining, SLM Solutions

EUROPE RESEARCH ROUNDUP- Allianz, Lundin Mining, SLM Solutions

  • November 11, 2022 11:12 PM WET | Reuters

Nov 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Allianz, Lundin Mining, and SLM Solutions, on Friday. HIGHLIGHTS * Allianz SE :

Read More...